Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TAI7
UPID:
REBL1_HUMAN
Alternative names:
Ras homolog enriched in brain like-1 c; Ras homolog enriched in brain-like protein 1; Rheb2
Alternative UPACC:
Q8TAI7; Q56VH8
Background:
GTPase RhebL1, also known as Ras homolog enriched in brain like-1 c, plays a pivotal role in cellular processes by binding GTP and exhibiting intrinsic GTPase activity. It is instrumental in activating NF-kappa-B-mediated gene transcription and promotes signal transduction through MTOR, further activating RPS6KB1. RhebL1 functions as a downstream target of the small GTPase-activating proteins TSC1 and TSC2.
Therapeutic significance:
Understanding the role of GTPase RhebL1 could open doors to potential therapeutic strategies.